

I hereby certify that this correspondence is being
mailed with the United States Postal Service as
First Class Mail in an envelope addressed to the
Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450

on January 18, 2006.

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1633
Patent Application
Docket No. USF-T144XCZ1
Serial No. 10/759,328

Zfu
#

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Maria Marvich, Ph.D.
Art Unit : 1633
Applicant : Said M. Sebti
Serial No. : 10/759,328
Filed : January 16, 2004
Conf. No. : 8343
For : RhoB as a Suppressor of Cancer Cell Growth, Cell Transformation, and
Metastasis

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO/SB/08
are being brought to the attention of the Examiner for consideration in connection with the
examination of the above-identified patent application. A copy of each cited reference is enclosed.

This information is being submitted subsequent to the later of three months after the filing
date of the present application or the mailing of the first Office Action on the merits, but before the
mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit
Account No. 19-0065.

The applicant respectfully asserts that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig
Patent Attorney

Registration No. 46,853


Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (2 pages); copies of references cited therein



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/759,328
Filing Date	January 16, 2004
First Named Inventor	Said M. Sebti
Group Art Unit	1633
Examiner Name	Maria B. Marvich, Ph.D.
Attorney Docket Number	USF-T144XCZ1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ADAMSON, P. <i>et al.</i> "Post-translational modifications of p21 ^{ras} proteins" <i>J Biol Chem</i> , 1992, 267:20033-20038.	
	R2	ADNANE, J. <i>et al.</i> "RhoB, not RhoA, represses the transcription of the transforming growth factor β type II receptor by a mechanism involving activator protein 1" <i>J Biol Chem</i> , 2002, 277:8500-8507.	
	R3	ARMSTRONG, S.A. <i>et al.</i> "CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB" <i>J Biol Chem</i> , 1995, 270:7864-7868.	
	R4	BARON, R. <i>et al.</i> "RhoB prenylation is driven by the three carboxylterminal amino acids of the protein: Evidenced <i>in vivo</i> by an anti-farnesyl cysteine antibody" <i>Proc Natl Acad Sci USA</i> , 2000, 97:11626-11631.	
	R5	CHANG, F. <i>et al.</i> "Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention" <i>Leukemia</i> , 2003, 17:1263-1293.	
	R6	CHARDIN, P. <i>et al.</i> "Coding sequence of human <i>rho</i> cDNAs clone 6 and clone 9" <i>Nucleic Acids Res.</i> 1988, 16: 2717.	
	R7	CLARK, E.A. <i>et al.</i> "Genomic analysis of metastasis reveals an essential role for RhoC" <i>Nature</i> , 2000, 406:532-535.	
	R8	DOWNWARD, J. "Targeting Ras signaling pathways in cancer therapy" <i>Nat Rev Cancer</i> , 2003, 3:11-22.	
	R9	FORGET, M.A. <i>et al.</i> "The expression of Rho proteins decreases with human brain tumor progression: potential tumor markers" <i>Clin Exp Metastasis</i> , 2002, 19(1):9-15.	
	R10	FRITZ, G. and KAINA, B. "Ras-related GTPase RhoB represses NF- κ B signaling" <i>J Biol Chem</i> , 2001, 276:3115-3122.	
	R11	FUKATA, M. <i>et al.</i> "Roles of Rho-family GTPases in cell polarisation and directional migration" <i>Curr Opin Cell Biol</i> , 2003, 15:590-597.	
	R12	GENBANK accession number X06820, "H. sapiens rhoB gene mRNA" October 24, 1996.	
	R13	GENBANK accession number CAA29968, "rhoB [Homo sapiens]" October 24, 1996.	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/759,328
				Filing Date	January 16, 2004
				First Named Inventor	Said M. Sebti
				Group Art Unit	1633
				Examiner Name	Maria B. Marvich, Ph.D.
Sheet	2	of	2	Attorney Docket Number	USF-T144XCZ1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	JIANG, K. <i>et al.</i> "Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis" <i>Mol Cell Biol</i> , 2004, 24:5565-5576.	
	R15	JIANG, K. <i>et al.</i> "EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation" <i>Oncogene</i> , 2004, 23:1136-1145.	
	R16	LEBOWITZ, P.F. <i>et al.</i> "Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription" <i>J Biol Chem</i> , 1997, 272:16093-16095.	
	R17	LIU, A-X. <i>et al.</i> "RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells" <i>Mol Cell Biol</i> , 2001, 21:6906-6912.	
	R18	MAZIERES, J. <i>et al.</i> "Loss of RhoB expression in human lung cancer progression" <i>Clin Cancer Res</i> , 2004, 10:2742-2750.	
	R19	NAKAMURA, T. <i>et al.</i> "Cloning of the RhoB gene from the mouse genome and characterization of its promoter region" <i>Biochem. Biophys. Res. Commun.</i> , 1996, 226(3):688-694.	
	R20	NOBES, C.D. and HALL, A. "Rho, Rac, and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia" <i>Cell</i> , 1995, 81:53-62.	
	R21	SEBTI, S.M. and HAMILTON, A.D. "Inhibition of Ras prenylation: A novel approach to cancer chemotherapy" 1997, 74:103-114.	
	R22	SYMONS, M. and RUSK, N. "Control of vesicular trafficking by Rho GTPases" <i>Curr Biol</i> , 2003, 13:R409-418.	
	R23	WANG, D-A and SEBTI, S.M. "Palmitoylated cysteine 192 is required for RhoB tumor suppressive and apoptotic activities" Presentation at the American Association for Cancer Research, Anaheim, CA, April 16-20, 2005, abstract.	
	R24	WANG, D-A. and SEBTI, S.M. "Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities" <i>J. Biol. Chem.</i> , 2005, 280:19243-19249.	
	R25	WELSH, C.F. "Rho GTPases as key transducers of proliferative signals in G ₁ cell cycle regulation" <i>Breast Cancer Res Treat</i> , 2004, 84:33-42.	
	R		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.